Meanwhile, METTL14 is down-regulated in cancers such as triple-negative breast cancer (TNBC) [157], esophageal cancer (EC) [158], osteosarcoma (OS) [16], hepatocellular carcinoma [121], and nephroblastoma [159], and its low expression has been associated with poor prognosis in cancer patients. Here, METTL14 is linked to hepatocellular carcinoma.